Healios K.K (TYO:4593) and Nobelpharma terminated discussions regarding a development and commercialization agreement for MultiStem in Japan, according to a Wednesday filing on the Tokyo Stock Exchange.
The decision follows unsuccessful renegotiations on the terms of the agreement after Healios opted not to proceed with a Phase 3 trial in Japan, as it was deemed unnecessary.
Price (JPY): $200.00, Change: $-1.0, Percent Change: -0.50%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.